Product Description
Dubermatinib is a novel, orally administered small molecule AXL kinase inhibitor affecting mesenchymal-epithelial transition while targeting oncogenesis and chemoresistance. (Sourced from: https://www.annalsofoncology.org/article/S0923-7534(20)40646-5/fulltext)
Mechanisms of Action: AXL Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell
Phase 1: Melanoma|Ovarian Cancer|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02729298 |
TP-0903-101 | P1 |
Completed |
Ovarian Cancer|Non-Small-Cell Lung Cancer|Melanoma|Colorectal Cancer |
2022-06-29 |
50% |
2023-10-18 |
Primary Endpoints|Treatments |
JapicCTI-194793 |
JapicCTI-194793 | P1 |
Unknown |
Melanoma|Ovarian Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer |
2021-12-31 |
|||
NCT04518345 |
OSU-19229 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-10-13 |
40% |
2023-10-18 |
Primary Endpoints |
NCT03013998 |
The Beat AML Trial | P2 |
Recruiting |
Acute Myeloid Leukemia |
2028-12-01 |
2025-12-18 |
||
NCT03572634 |
TP-0903-102 | P2 |
Terminated |
Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2020-01-21 |
24% |
2023-10-18 |
Primary Endpoints|Treatments |